8-KEarnings & ResultsShareholder MattersExhibits & Filings

DARDEN RESTAURANTS INC 8-K Report, Financial Results (Sep 20, 2018)

Filed September 20, 2018For Securities:DRI

Summary

Darden Restaurants, Inc. (DRI) filed an 8-K report on September 20, 2018, detailing its first-quarter fiscal year 2019 results and a positive outlook. The company reported strong performance for the quarter and, importantly, raised its financial guidance for the full fiscal year, signaling confidence in continued growth and operational execution. Beyond the financial performance, the filing also includes the results of Darden's Annual Shareholder Meeting held on September 19, 2018. All director nominees were overwhelmingly elected, and shareholders provided advisory approval for executive compensation and ratified the appointment of KPMG LLP as the independent auditor. Notably, a shareholder proposal regarding antibiotic use in the supply chain did not pass, indicating management's current approach to this issue is favored by the majority of shareholders.

Key Highlights

  • 1Darden Restaurants reported strong first-quarter fiscal year 2019 results.
  • 2The company increased its financial outlook for the full fiscal year 2019.
  • 3All 8 director nominees were elected with a significant majority of shareholder votes.
  • 4Shareholders provided advisory approval for the company's executive compensation plan.
  • 5KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2019.
  • 6A shareholder proposal requesting a report on eliminating medically important antibiotics for disease prevention in the supply chain was not approved.

Frequently Asked Questions

The filing announces Darden's first-quarter fiscal year 2019 results and indicates a positive financial performance. Crucially, the company raised its financial outlook for the entire fiscal year, suggesting expected continued strength and growth.

At the annual meeting, all eight director nominees were overwhelmingly elected. Shareholders also approved executive compensation on an advisory basis and ratified KPMG LLP as the company's independent auditor for the upcoming fiscal year.

Yes, a shareholder proposal asking Darden to issue a report on the feasibility of eliminating the use of medically important antibiotics for disease prevention in its supply chain was not approved by shareholders.

No, as stated in the filing, the financial results and news release furnished under Item 2.02 are not deemed 'filed' for purposes of Section 18 of the Exchange Act and generally do not trigger liability under that section.